Riskpilot← Back to searchSign inGet full accessDexsin AB
ABActiveOrg 5593162711Krossbacken 25Research and experimental development on natural sciences and engineering · NACE 7210Est. 20210 employees
Revenue 2024
—
EBITDA margin
—
Equity ratio
—
Financial strength
Net profit 2024
—
0 employees
| Revenue | — | — |
| EBITDA | SEK 0 | — |
| Net profit | — | — |
| Total assets | — | — |
| Equity | — | — |
| Employees | 0 | — |
Legal name
Dexsin AB
Org number
5593162711
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
6 maj 2021
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Konsulttjänster inom teknik, forskning, vetenskap och statistik, men även inom fysisk träning, musik och musikproduktion.
Address
Krossbacken 25
Email
andreas.k.j.blomqvist@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 126 | 160 | 70 | — |
| Staff expenses | — | — | — | — |
| EBITDA | 104 | 8 | 10 | 0 |
| Depreciation & amort. | −93 | −0 | −0 | — |
| EBIT | 11 | 8 | 10 | 0 |
| Net financials | — | — | — | — |
| Profit before tax | 11 | 9 | 10 | 0 |
| Tax | −2 | −2 | −2 | — |
| Net profit | 9 | 7 | 8 | — |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 36 | 37 | 35 | — |
| Equity | 31 | 32 | 33 | — |
| Long-term debt | 0 | 0 | 0 | — |
| Short-term debt | 2 | 5 | 2 | — |
| Total debt | 2 | 5 | 2 | — |
EBITDA margin
0.0%
This company
15.8%
Market median
-100% vs market
20212024
Equity ratio
0.0%
This company
38.2%
Market median
-100% vs market
20212024
Return on equity
0.0%
This company
18.4%
Market median
-100% vs market
20212024
Net profit margin
0.0%
This company
8.1%
Market median
-100% vs market
20212024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212024
Debt / equity
-1.00×
This company
0.62×
Market median
+261% vs market
20212024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-05-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2024 | |
| Board of Directors | 2022 | |
| Former (1) | ||
| Deputy Board Member | 2022 – 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Dexsin AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jennifer Lynn Teodorsson Blomqvist | Deputy Board Member | 0 companies |
| Andreas Karl Johan Blomqvist | Board of Directors | 0 companies |
| Peter Carl Gustaf Blomqvist | Deputy Board Member | 0 companies |